An Obama administration proposal to reduce the number of years that drugmakers have exclusive rights to biologic drugs could be pre-empted by the Trans-Pacific Partnership's proposed timeline of 12 years. The Pharmaceutical Research and Manufacturers of America is pushing for 12-year exclusivity, saying that it is necessary for drugmakers to yield returns on their investments in research and development. "You won't have the new drugs unless you have the 12 years," PhRMA spokesman Mark Grayson said. "You need to give the people the incentive to develop."
Published in Brief: